Author pages are created from data sourced from our academic publisher partnerships and public sources.
Metabolic effects of a growth hormone-releasing factor in patients with HIV.
- J. Falutz, S. Allas, +9 authors S. Grinspoon
- The New England journal of medicine
- 6 December 2007
BACKGROUND Visceral adipose tissue accumulates during antiretroviral therapy in many patients who are infected with the human immunodeficiency virus (HIV); this process is associated with an… Expand
Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension
- J. Falutz, D. Potvin, +10 authors S. Grinspoon
- Journal of acquired immune deficiency syndromes
- 1 March 2010
Background:HIV-infected patients receiving antiretroviral therapy often demonstrate excess visceral fat. A growth hormone-releasing factor, tesamorelin, may selectively reduce visceral fat in this… Expand
Delay in cART Initiation Results in Persistent Immune Dysregulation and Poor Recovery of T-Cell Phenotype Despite a Decade of Successful HIV Suppression
Background Successful combination antiretroviral therapy (cART) increases levels of CD4+ T-cells, however this increase may not accurately reflect long-term immune recovery since T-cell dysregulation… Expand
Frailty in people aging with human immunodeficiency virus (HIV) infection.
- Thomas D Brothers, S. Kirkland, +4 authors K. Rockwood
- The Journal of infectious diseases
- 15 October 2014
The increasing life spans of people infected with human immunodeficiency virus (HIV) reflect enormous treatment successes and present new challenges related to aging. Even with suppression of viral… Expand
Whey proteins as a food supplement in HIV-seropositive individuals.
- G. Bounous, S. Baruchel, J. Falutz, P. Gold
- Clinical and investigative medicine. Medecine…
- 1 June 1993
On the basis of numerous animal experiments, a pilot study was undertaken to evaluate the effect of undenatured, biologically active, dietary whey protein in 3 HIV-seropositive individuals over a… Expand
A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity
Objectives:Aging with HIV is associated with multisystem vulnerability that might be well characterized by frailty. We sought to construct a frailty index based on health deficit accumulation in a… Expand
Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus.
- C. Wanke, J. Falutz, A. Shevitz, J. Phair, D. Kotler
- Clinical infectious diseases : an official…
- 15 January 2002
In recent years, a spectrum of metabolic and morphologic alterations has emerged among patients infected with human immunodeficiency virus (HIV) receiving antiretroviral treatment. Changes observed… Expand
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation
Objective:To investigate the effects of TH9507, a novel growth hormone releasing factor, on abdominal fat accumulation, metabolic and safety parameters in HIV-infected patients with central fat… Expand
HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls
Background:Frailty is an age-related syndrome of decreased physiological reserve and resistance to stressors, associated with increased morbidity and mortality in the general elderly population. An… Expand
Aging with HIV vs. HIV Seroconversion at Older Age: A Diverse Population with Distinct Comorbidity Profiles
Objective People aging with HIV might have different health conditions compared with people who seroconverted at older ages. The study objective was to assess the prevalence of, and risk factors for,… Expand